InvestorsHub Logo
Followers 13
Posts 724
Boards Moderated 0
Alias Born 11/17/2011

Re: MrW post# 58938

Saturday, 04/26/2014 2:41:45 PM

Saturday, April 26, 2014 2:41:45 PM

Post# of 403035
Haha yep - math is powerful, logical, and does not yield to subjective critique or conjecture. And the math says buy CTIX and hold most of it for a couple years. Of course some subjective critique may be needed to get some starting assumptions: go to Pharmacyclics' website, check out their R&D section and their pipeline, go to Cellceutix's website, check out their pipeline section, compare. Then do math: at $150 pcyc had a cap of 11.25B, if we give equal valuation and assume today's OS numbers for simplicity, ctix will be at $107 eventually. I would argue CTIX's pipeline has advantages regarding both strength and breadth across different pharmaceutical catagories, so even as share numbers may change with respect to Aspire,total OS, etc., $107 is potentially a conservative value. Of course trial results will be the determining factor.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News